April 29th 2025
Insurance hurdles and the complexities of prior authorization create barriers to care, according to oncologists in a new survey by Sermo.
Go To PER in Chicago
May 30, 2025 - June 3, 2025
Register Now!
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Lung Cancer Tumor Board: Enhancing Precision Medicine in NSCLC Through Advancements in Molecular Testing and Optimal Therapy Selection
View More
Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
(CME Credit) Advancing Outcomes in Limited-Stage Small Cell Lung Cancer: From Evidence to Practice
View More
Study: The Cost-effectiveness of Polivy Depends on Outcomes
June 20th 2022A study in the journal Blood has found that the cost-effectiveness of the Polivy treatment regimen used to treat patients with diffuse large B-cell lymphoma would decrease if the five-year progression-free survival decreased.
Read More
PBM Exclusions Increasing, Finds New Analysis
June 7th 2022Xcenda’s review of the three largest PBMs—CVS Caremark, Express Scripts, and OptumRx—finds they are excluding medicines in classes where generics are not available or for serious conditions, such as oncology and autoimmune disorders.
Read More
Aetna Adds Recently Approved Drugs to Precertification List
May 18th 2022Aetna has made available four specialty drugs that were approved early in 2022 through prior authorization. These include a biosimilar, a CAR-T immunotherapy, and therapies for macular degeneration and a rare auto-immune disease.
Read More